The company says that the market for drugs in India is valued around Rs 390 crore
National drugmaker Lupine Ltd on Tuesday launched the treatment of erectile dysfunction – Cialis in India through an exclusive licensing agreement with Eli Lilly.
Lupine acquired the rights to market, promote and distribute Lilly Cialis (Tadalafil) erectile dysfunction (ED) product, while Lilly will be responsible for manufacturing and importing the product, the company said in a statement.
Rajeev Sibal said the launch of Cialis marks Lupine’s entry into the rapidly growing PDE-5 inhibitor market, which will address unmet medical need in ED space in India.
Inhibitors of PDE-5 (Phosphodiesterase Type 5) are recommended as first-line treatment in cases of erectile dysfunction.
The company said the PDE-5 market in India is valued at around Rs 390 crore.
The size of the market has doubled since 2012 and is growing annually by 15%.
The tablet Cialis is available in doses of 10 mg and 20 mg. The product is currently marketed in more than 100 countries.
Lupine is already promoting and distributing Lilly’s Huminsulin range of products and fast acting insulin analogues under the Lispro and Eglucent brands.
The CEO of Eli Lilly and Company (India) Pvt Ltd, Edgard Olaizola, said the launch of Cialis is an expansion of the company’s relationship with Lupine, with whom it has successfully partnered in the past.
“Today, erectile dysfunction is a major medical condition affecting large numbers of Indian men, this partnership will help expand our reach to more patients. Lilly is committed to bringing innovative products to India,” said Olaizola.